This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macejak, D. G.
Right arrow Articles by Couture, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macejak, D. G.
Right arrow Articles by Couture, L.

 Previous Article  |  Next Article 

Journal of Virology, September 1999, p. 7745-7751, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Adenovirus-Mediated Expression of a Ribozyme to c-myb mRNA Inhibits Smooth Muscle Cell Proliferation and Neointima Formation In Vivo

Dennis G. Macejak,1,* Hua Lin,2 Saiphone Webb,1 Jennifer Chase,1 Kristi Jensen,1 Thale C. Jarvis,1 Jeffrey M. Leiden,2 and Larry Couture1,dagger

Ribozyme Pharmaceuticals, Inc., Boulder, Colorado 80301,1 and Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 606372

Received 16 March 1999/Accepted 18 May 1999

Smooth muscle cell (SMC) proliferation is an important component of restenosis in response to injury after balloon angioplasty. Inhibition of proliferation in vivo can limit neointima hyperplasia in animal models of restenosis. Ribozymes against c-myb mRNA have been shown to be effective inhibitors of SMC proliferation in vitro. The effectiveness of adenovirus as a gene therapy vector in animal models of restenosis is well documented. In order to test the utility of ribozymes to inhibit SMC proliferation by a gene therapy approach, recombinant adenovirus expressing ribozymes against c-myb mRNA was generated and tested both in vitro and in vivo. This adenovirus ribozyme vector is shown to inhibit SMC proliferation in culture and neointima formation in a rat carotid artery balloon injury model of restenosis.


* Corresponding author. Mailing address: 2950 Wilderness Place, Boulder, CO 80301. Phone: (303) 546-8153. Fax: (303) 449-6500. E-mail: macejad{at}rpi.com.

dagger Present address: City of Hope National Medical Center, Duarte, CA 91010.


Journal of Virology, September 1999, p. 7745-7751, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Remillard, C. V., Tigno, D. D., Platoshyn, O., Burg, E. D., Brevnova, E. E., Conger, D., Nicholson, A., Rana, B. K., Channick, R. N., Rubin, L. J., O'Connor, D. T., Yuan, J. X.-J. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 292: C1837-C1853 [Abstract] [Full Text]  
  • You, X.-M., Mungrue, I. N., Kalair, W., Afroze, T., Ravi, B., Sadi, A. M., Gros, R., Husain, M. (2003). Conditional Expression of a Dominant-Negative c-Myb in Vascular Smooth Muscle Cells Inhibits Arterial Remodeling After Injury. Circ. Res. 92: 314-321 [Abstract] [Full Text]  
  • Kotani, M., Fukuda, N., Ando, H., Hu, W.-Y., Kunimoto, S., Saito, S., Kanmatsuse, K. (2003). Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc Res 57: 265-276 [Abstract] [Full Text]  
  • Jiang, H. Y., Petrovas, C., Sonenshein, G. E. (2002). RelB-p50 NF-{kappa}B Complexes Are Selectively Induced by Cytomegalovirus Immediate-Early Protein 1: Differential Regulation of Bcl-xL Promoter Activity by NF-{kappa}B Family Members. J. Virol. 76: 5737-5747 [Abstract] [Full Text]  
  • Lowe, H. C., Oesterle, S. N., Khachigian, L. M. (2002). Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 39: 183-193 [Abstract] [Full Text]  
  • Sriram, V., Patterson, C. (2001). Cell Cycle in Vasculoproliferative Diseases : Potential Interventions and Routes of Delivery. Circulation 103: 2414-2419 [Abstract] [Full Text]  
  • Gu, J.-L., Pei, H., Thomas, L., Nadler, J. L., Rossi, J. J., Lanting, L., Natarajan, R. (2001). Ribozyme-Mediated Inhibition of Rat Leukocyte-Type 12-Lipoxygenase Prevents Intimal Hyperplasia in Balloon-Injured Rat Carotid Arteries. Circulation 103: 1446-1452 [Abstract] [Full Text]  
  • LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., Hauswirth, W. W. (2000). Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. USA 10.1073/pnas.210319397v1 [Abstract] [Full Text]  
  • LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., Hauswirth, W. W. (2000). Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. USA 97: 11488-11493 [Abstract] [Full Text]  
  • Patricia, M. K., Natarajan, R., Dooley, A. N., Hernandez, F., Gu, J.-L., Berliner, J. A., Rossi, J. J., Nadler, J. L., Meidell, R. S., Hedrick, C. C. (2001). Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells. Circ. Res. 88: 659-665 [Abstract] [Full Text]  
  • Qian, H. S., Channon, K., Neplioueva, V., Wang, Q., Finer, M., Tsui, L., George, S. E., McArthur, J. (2001). Improved Adenoviral Vector for Vascular Gene Therapy : Beneficial Effects on Vascular Function and Inflammation. Circ. Res. 88: 911-917 [Abstract] [Full Text]  
  • FRANCIS, S. C., RAIZADA, M. K., MANGI, A. A., MELO, L. G., DZAU, V. J., VALE, P. R., ISNER, J. M., LOSORDO, D. W., CHAO, J., KATOVICH, M. J., BERECEK, K. H. (2001). Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?. Physiol. Genomics 7: 79-94 [Abstract] [Full Text]